Myriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $218.45 Million

Equities research analysts forecast that Myriad Genetics, Inc. (NASDAQ:MYGN) will announce $218.45 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Myriad Genetics’ earnings, with the highest sales estimate coming in at $226.28 million and the lowest estimate coming in at $215.75 million. Myriad Genetics posted sales of $194.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 12.6%. The business is expected to announce its next quarterly earnings results on Tuesday, February 5th.

According to Zacks, analysts expect that Myriad Genetics will report full year sales of $872.12 million for the current financial year, with estimates ranging from $859.02 million to $891.40 million. For the next financial year, analysts expect that the firm will report sales of $939.49 million, with estimates ranging from $895.80 million to $1.00 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, November 6th. The company reported $0.43 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.13. The business had revenue of $202.30 million during the quarter, compared to analyst estimates of $203.20 million. Myriad Genetics had a return on equity of 10.07% and a net margin of 7.07%. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 EPS.

MYGN has been the subject of a number of research analyst reports. Piper Jaffray Companies upgraded Myriad Genetics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $53.00 in a research report on Wednesday, October 10th. Zacks Investment Research downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Monday. BidaskClub downgraded Myriad Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 5th. Barclays dropped their target price on Myriad Genetics from $23.00 to $21.00 and set an “underweight” rating for the company in a research report on Thursday, January 3rd. Finally, Needham & Company LLC started coverage on Myriad Genetics in a research report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $36.00 target price for the company. Two research analysts have rated the stock with a sell rating, six have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.70.

Hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP bought a new stake in Myriad Genetics in the third quarter worth $130,000. First Quadrant L P CA bought a new stake in Myriad Genetics in the third quarter worth $201,000. Ibex Investors LLC bought a new stake in Myriad Genetics in the third quarter worth $202,000. Parametrica Management Ltd bought a new stake in Myriad Genetics in the third quarter worth $204,000. Finally, CHICAGO TRUST Co NA boosted its holdings in Myriad Genetics by 50.0% in the fourth quarter. CHICAGO TRUST Co NA now owns 7,500 shares of the company’s stock worth $218,000 after acquiring an additional 2,500 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Shares of MYGN traded down $0.77 during trading hours on Friday, reaching $29.49. 7,630 shares of the company’s stock traded hands, compared to its average volume of 1,314,775. The company has a market cap of $2.28 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.97 and a beta of 0.58. The company has a current ratio of 3.17, a quick ratio of 2.83 and a debt-to-equity ratio of 0.23. Myriad Genetics has a 12 month low of $26.80 and a 12 month high of $50.44.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply